Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple

#KYTX Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/KYTX/kyverna-therap...

Trade Alerts, Wednesday December 17, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Wed Dec 17th - #SNGX #DFSC #VTGN #PLCE #KYTX #IMNM #SPIR - More: crystalequityresearch.com/trade-alerts... - #smallcap

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of

#KYTX Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

www.stocktitan.net/news/KYTX/kyverna-therap...

Most Searched, Monday December 15, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 15th - #QUBT #KYTX #NVTS #JBLU #CLYM #RR #BEAT #BTBT #RADX #DNN #ARTV #BITF #MIST #PLUG #BBAI #USAR #TLRY #ONDS #IRBT #CLSK - More: crystalequityresearch.com/most-searche... - #smallcap

Trade Alerts, Monday December 15, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Mon Dec 15th - #UAG #RADX #MASK #QIPT #KYTX #KVHI #IMNM #ARTV - More: crystalequityresearch.com/trade-alerts... - #smallcap

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock Kyverna Therapeutics (Nasdaq: KYTX) announced a proposed underwritten public offering of $100,000,000 of common stock on December 15, 2025, with a 30-day underwriter option to purchase up to an additional $15,000,000 of shares at the public offering price, less underwriting discounts and commissions.All shares will be sold by Kyverna and the offering is being led by J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities. The offering is subject to market and other conditions and will be made pursuant to an effective Form S-3 shelf registration (File No. 333-286180); a preliminary prospectus supplement will be filed with the SEC.

#KYTX Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/KYTX/kyverna-therap...

📢 Stocks Trending NOW: #IRBT #TSLA #OCG #RADX #MIST #NOW #AMCI #CGC #KYTX #IMNM

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome Kyverna Therapeutics (Nasdaq: KYTX) announced positive topline results from the registrational Phase 2 KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome (SPS) on December 15, 2025. In 26 dosed patients at the Week 16 primary analysis, miv-cel achieved a median 46% improvement in timed 25-foot walk (T25FW) vs baseline (p=0.0002) and 81% of patients exceeded a clinically meaningful 20% T25FW improvement. All secondary endpoints showed highly significant benefits (all p<0.0001).Safety was manageable with no high-grade CRS or ICANS; Grade 3/4 neutropenia was observed. Kyverna plans a BLA submission in 1H 2026 and will present full data at a 2026 medical conference.

#KYTX Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

www.stocktitan.net/news/KYTX/kyverna-therap...

BREAKING NEWS: ( NASDAQ: #KYTX ) Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

#KYTX Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/KYTX/kyverna-therap...

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance Kyverna Therapeutics (NASDAQ: KYTX) closed a debt facility with Oxford Finance for up to $150 million, drawing an initial $25 million on November 3, 2025. The facility includes an initial tranche structure (totaling up to $150M across four tranches) and matures on October 1, 2030. Kyverna said the financing strengthens liquidity and supports late-stage programs in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG) while accelerating pre-launch work.Guidance updated: topline registrational SPS data now expected in early 2026 (narrowed from 1H 2026); BLA filing for SPS targeted in 1H 2026; MG Phase 3 enrollment to begin by end of 2025. Additional program readouts and an IND filing for KYV-102 are planned in 2025–2026.

#KYTX Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

www.stocktitan.net/news/KYTX/kyverna-therap...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PPBT 170% OTM
2. #CRCL 91% OTM
3. #CMBM 74% OTM
4. #KYTX 59% OTM
5. #NKLR 58% OTM

#OptionFlow #OptionsTrading #Trading

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 Kyverna Therapeutics (NASDAQ: KYTX) announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis on October 29, 2025.In six treated patients (data cutoff Oct 3, 2025) a single 1×10^8 CAR+T dose produced mean MG-ADL -8.0 and QMG -7.7 point changes at 24 weeks; 100% (6/6) met co-primary clinical response thresholds and 100% were free of several background immunosuppressive treatments through 24 weeks. Safety showed no Grade ≥3 CRS and no ICANS; one Grade 4 neutropenia resolved to Grade 1 by cutoff.

#KYTX Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

www.stocktitan.net/news/KYTX/kyverna-therap...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CODX 90% OTM
2. #KYTX 59% OTM
3. #BIDU 55% OTM
4. #ASST 51% OTM
5. #RGTI 50% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#KYTX, #BIDU, #ASST, #RGTI, #USAR

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #KYTX ) Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 Kyverna Therapeutics (Nasdaq: KYTX) reported Phase 1 investigator-initiated trial results for KYV-101 in difficult-to-treat rheumatoid arthritis presented at ACR Convergence 2025.In six ACPA-positive, treatment-refractory patients given a single 1×108 KYV-101 infusion (follow-up 28–175 days), CAR T cells expanded rapidly (peak 14–21 days), B cells were depleted in all patients, and profound reductions in ACPA and RF-IgM were observed. Four of six achieved ACR20 and two achieved ACR50. Safety showed no high-grade CRS or ICANS. These data supported initiation of the randomized Phase 2 portion, with enrollment completed.

#KYTX Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

www.stocktitan.net/news/KYTX/kyverna-therap...

BREAKING NEWS: ( NASDAQ: #KYTX ) Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS Kyverna Therapeutics (Nasdaq: KYTX) announced updated Phase 1 data for KYV-101 in progressive multiple sclerosis (MS) to be presented at the 2025 ECTRIMS Congress. The data comes from investigator-initiated trials at Stanford Medicine and UCSF.Key findings include: robust CAR T-cell penetration into the central nervous system, improved disability status scores (EDSS), and a tolerable safety profile with no high-grade adverse events. Stanford's trial enrolled 6 patients (4 treated) while UCSF's study included 2 patients, all showing disease stabilization or improvement. The therapy demonstrated successful immune reset potential, evidenced by B-cell reconstitution to a naive phenotype in multiple patients.

#KYTX Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

www.stocktitan.net/news/KYTX/kyverna-therap...

First CAR-T Therapy Shows Promise in Myasthenia Gravis: Kyverna's KYV-101 Phase 2 Data Coming at AANEM Kyverna Therapeutics to present interim Phase 2 data for KYV-101 in myasthenia gravis, featuring 6 patients with 9-month follow-up. Phase 3 trial initiation expected by end of 2025.

#KYTX Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

www.stocktitan.net/news/KYTX/kyverna-therap...

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event Kyverna Therapeutics (Nasdaq: KYTX) announced details of its Phase 3 registrational trial design for KYV-101, a CD19-directed CAR T-cell therapy, in myasthenia gravis (MG). The KYSA-6 Phase 2/3 trial will enroll approximately 60 patients randomized 1:1 to receive either KYV-101 or standard-of-care therapy.The trial aims to demonstrate KYV-101's potential to deliver durable, drug-free, disease-free remission in MG patients. Key endpoints include changes in MG-ADL and QMG scores at 24 weeks. The company expects to initiate Phase 3 enrollment by year-end 2025 and will report interim Phase 2 data in Q4 2025.The therapy is also being developed for stiff person syndrome (SPS), with positive longer-term follow-up data reported from compassionate use patients in both indications.

#KYTX Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

www.stocktitan.net/news/KYTX/kyverna-therap...

Leading Indicators, Monday July 28, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator - #OBIO #PDFS #SPWH #TCBK #UPLD #WVE #ZNTL #ACCO #BORR #DEC #EAI #FF #KRP #PRO #QUAD #RIG #SES #NESR #MFIN #LGHL #KYTX #IMMP #FATE #EVAX #DAKT #BAND #AOB - More: crystalequityresearch.com/ieading-indi... - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks overbought with declining relative strength, Wed Jun 11th - #NEGG #LIMN #KYTX #FTEK #EYEN #CMPX #BIRD #AKBA #YEXT #SANA #THRD #ULBI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results Kyverna Therapeutics (NASDAQ: KYTX) reported significant progress in Q1 2025 and provided key business updates. The company completed enrollment in its registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS), with topline data and BLA filing expected in 1H 2026. Following FDA alignment, Kyverna is advancing into a Phase 3 trial for myasthenia gravis (MG), with Phase 2 data anticipated in 2H 2025. The company maintains a strong financial position with $242.6 million in cash, providing runway into 2027. Q1 financial results showed R&D expenses of $37.4M and a net loss of $44.6M. The company implemented a 16% workforce reduction and plans to host a KOL event in Q3 2025 focusing on its neuroinflammation franchise. Development continues for KYV-102, with an IND filing planned for 2H 2025.

#KYTX Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/KYTX/kyverna-therap...

Kyverna Advances Multiple Phase 2 Trials with $286M War Chest for Autoimmune Breakthroughs Kyverna advances key autoimmune trials with 70% enrollment in SPS study. $286M cash runway supports multiple Phase 2 readouts through 2026. Full pipeline details inside.

#KYTX Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/KYTX/kyverna-therap...

Kyverna Therapeutics Set to Showcase Innovations at Leerink Partners Global Biopharma Conference Join Kyverna Therapeutics at the upcoming Leerink Partners Global Biopharma Conference in Miami, where they'll present novel advances in cell therapy for autoimmune diseases.

Kyverna Therapeutics Set to Showcase Innovations at Leerink Partners Global Biopharma Conference #United_States #Miami #Biopharma #Kyverna_Therapeutics #KYTX

Levi & Korsinsky Alerts Investors About Deadline in Kyverna Therapeutics Class Action Lawsuit Levi & Korsinsky, LLP has reminded investors of a key deadline concerning a class action lawsuit against Kyverna Therapeutics, Inc. Investors must act by February 7, 2025.

Levi & Korsinsky Alerts Investors About Deadline in Kyverna Therapeutics Class Action Lawsuit #United_States #New_York #Levi_Korsinsky #Kyverna_Therapeutics #KYTX

Kyverna Therapeutics Investors Rally for Opportunity in Securities Fraud Lawsuit Investors in Kyverna Therapeutics Inc. are urged to join a securities fraud class action lawsuit following undisclosed trial data that affected their investments.

Kyverna Therapeutics Investors Rally for Opportunity in Securities Fraud Lawsuit #USA #Los_Angeles #Glancy_Prongay #Kyverna_Therapeutics #KYTX

Kyverna Therapeutics, Inc. Class Action Update: Deadlines Approaching and Investor Rights at Risk Kyverna Therapeutics, Inc. faces a class action lawsuit with a lead plaintiff deadline of February 7, 2025. Investors are urged to register now.

Kyverna Therapeutics, Inc. Class Action Update: Deadlines Approaching and Investor Rights at Risk #USA #New_York #The_Gross_Law_Firm #Kyverna_Therapeutics #KYTX

Investors Warned About Lawsuit Against Kyverna Therapeutics - Act by Deadline ClaimsFiler informs investors in Kyverna Therapeutics about a class action lawsuit deadline. Investors should file claims by February 7, 2025.

Investors Warned About Lawsuit Against Kyverna Therapeutics - Act by Deadline #United_States #New_Orleans #ClaimsFiler #Kyverna_Therapeutics #KYTX